Multibagger Alert: This SME Stock Turns ₹1.17 Lakh Investment into ₹6.4 Lakh in Just 1.5 Years—Check How!

The Indian stock market is seeing a surge in small and medium-sized enterprise (SME) initial public offerings (IPOs). While many of these new listings have had mixed results, some earlier IPOs have turned out to be real success stories for investors.

One such example is Sudarshan Pharma Industries, which launched its IPO in March 2023. At the time, it wasn’t a big hit with investors, receiving just 1.06 times the subscription. However, the stock has since delivered impressive returns, rising by a huge 448% over the past 1.5 years. This shows that even IPOs with a quiet start can surprise the market.

Sudarshan Pharma Industries IPO

Sudarshan Pharma’s IPO opened for public subscription on March 9, 2023, with a price range of ₹71 to ₹73 per share. Retail investors needed to invest a minimum of ₹1.17 lakh to participate. The stock made a flat entry at ₹73 on March 22, 2023, when it listed on the BSE SME platform.

Sudarshan Pharma’s Share Performance

Since its market debut, Sudarshan Pharma has rewarded patient investors. As of October 14, 2024, the stock surged by 448% from its issue price. It reached a 52-week high of ₹452.70 on October 3, 2024, after hitting a 52-week low of ₹58.20 in June. Last month alone, the stock gained 124%, but in October, it saw a slight dip, falling by 5%.

If an investor had put ₹1.17 lakh into this IPO, their investment would have grown to ₹6.4 lakh in just 1.5 years.

Recent Developments at Sudarshan Pharma

On October 14, 2024, Sudarshan Pharma announced the acquisition of 2,09,100 shares of Ishwari Healthcare Private Limited, representing 51% of its equity. With this, Ishwari Healthcare will become a subsidiary of Sudarshan Pharma.

Additionally, on September 30, 2024, the company’s board approved a plan to split its shares. The current face value of ₹10 per share will be divided into 10 shares of ₹1 each. This stock split will make the shares more affordable for smaller investors.

Sudarshan Pharma Industries’ IPO might have started slowly, but its strong performance over time has proven it to be a multibagger, turning a modest investment into substantial returns in just over a year and a half. Investors looking for long-term gains should keep an eye on such opportunities in the SME sector.